These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 8345202)

  • 21. Immunization with a tetraepitopic lipid core peptide vaccine construct induces broadly protective immune responses against group A streptococcus.
    Olive C; Ho MF; Dyer J; Lincoln D; Barozzi N; Toth I; Good MF
    J Infect Dis; 2006 Jun; 193(12):1666-76. PubMed ID: 16703510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mapping the immunodeterminants of the complete streptococcal M6 protein molecule. Identification of an immunodominant region.
    Fischetti VA; Windels M
    J Immunol; 1988 Nov; 141(10):3592-9. PubMed ID: 2460540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Variable susceptibility to opsonophagocytosis of group A streptococcus M-1 strains by human immune sera.
    Villaseñor-Sierra A; McShan WM; Salmi D; Kaplan EL; Johnson DR; Stevens DL
    J Infect Dis; 1999 Dec; 180(6):1921-8. PubMed ID: 10558949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. M protein conserved region antibodies opsonise multiple strains of Streptococcus pyogenes with sequence variations in C-repeats.
    Vohra H; Dey N; Gupta S; Sharma AK; Kumar R; McMillan D; Good MF
    Res Microbiol; 2005 May; 156(4):575-82. PubMed ID: 15862457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New 30-valent M protein-based vaccine evokes cross-opsonic antibodies against non-vaccine serotypes of group A streptococci.
    Dale JB; Penfound TA; Chiang EY; Walton WJ
    Vaccine; 2011 Oct; 29(46):8175-8. PubMed ID: 21920403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity of a polypeptide fragment of the streptococcal group A M protein conjugated with an acrylic acid N-vinylpyrrolidone copolymer.
    Lyampert IM; Semenova EN; Sanina VYu ; Puchkova NG; Nekrasov AV
    Biomed Sci; 1991; 2(4):410-4. PubMed ID: 1797145
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
    Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
    Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opsonic antibodies evoked by hybrid peptide copies of types 5 and 24 streptococcal M proteins synthesized in tandem.
    Beachey EH; Gras-Masse H; Tarter A; Jolivet M; Audibert F; Chedid L; Seyer JM
    J Exp Med; 1986 Jun; 163(6):1451-8. PubMed ID: 3519829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Group A streptococcus expresses a trio of surface proteins containing protective epitopes.
    Niedermeyer SE; Penfound TA; Hohn C; Li Y; Homayouni R; Zhao J; Dale JB
    Clin Vaccine Immunol; 2014 Oct; 21(10):1421-5. PubMed ID: 25080552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of unique human TCR V beta specificities for a family of streptococcal superantigens represented by rheumatogenic serotypes of M protein.
    Watanabe-Ohnishi R; Aelion J; LeGros L; Tomai MA; Sokurenko EV; Newton D; Takahara J; Irino S; Rashed S; Kotb M
    J Immunol; 1994 Feb; 152(4):2066-73. PubMed ID: 8120408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward the development of a synthetic group a streptococcal vaccine of high purity and broad protective coverage.
    Horváth A; Olive C; Karpati L; Sun HK; Good M; Toth I
    J Med Chem; 2004 Jul; 47(16):4100-4. PubMed ID: 15267249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of an epitope of type 1 streptococcal M protein that is shared with a 43-kDa protein of human myocardium and renal glomeruli.
    Kraus W; Dale JB; Beachey EH
    J Immunol; 1990 Dec; 145(12):4089-93. PubMed ID: 1701783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Creation and analysis of a bank of chromosomal genes of Streptococcus group A].
    Nesterchuk LB; Gupalova TV; Kolesnichenko TG; Suvorov AN; Golubkov VI
    Mol Gen Mikrobiol Virusol; 1989 Feb; (2):42-6. PubMed ID: 2661999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative in silico analysis of two vaccine candidates for group A streptococcus predicts that they both may have similar safety profiles.
    Shaila MS; Nayak R; Prakash SS; Georgousakis M; Brandt E; McMillan DJ; Batzloff MR; Pruksakorn S; Good MF; Sriprakash KS
    Vaccine; 2007 May; 25(18):3567-73. PubMed ID: 17293014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial.
    Kotloff KL; Corretti M; Palmer K; Campbell JD; Reddish MA; Hu MC; Wasserman SS; Dale JB
    JAMA; 2004 Aug; 292(6):709-15. PubMed ID: 15304468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Studies on group A streptococcal M-proteins: purification of type 5 M-protein and comparison of its amino terminal sequence with two immunologically unrelated M-protein molecules.
    Manjula BN; Fischetti VA
    J Immunol; 1980 Jan; 124(1):261-7. PubMed ID: 6985640
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structure-based group A streptococcal vaccine design: Helical wheel homology predicts antibody cross-reactivity among streptococcal M protein-derived peptides.
    Aranha MP; Penfound TA; Spencer JA; Agarwal R; Baudry J; Dale JB; Smith JC
    J Biol Chem; 2020 Mar; 295(12):3826-3836. PubMed ID: 32029479
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular structure and immunochemistry of streptococcal M-protein].
    Ookuni H
    Tanpakushitsu Kakusan Koso; 1990 Nov; 35(15):2839-51. PubMed ID: 1701908
    [No Abstract]   [Full Text] [Related]  

  • 39. Protection against group A streptococcal infection by vaccination with self-adjuvanting lipid core M protein peptides.
    Olive C; Hsien K; Horváth A; Clair T; Yarwood P; Toth I; Good MF
    Vaccine; 2005 Mar; 23(17-18):2298-303. PubMed ID: 15755615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of a mucosal immune response to the streptococcal M protein by intramuscular administration of a PADRE-ASREAK peptide.
    Pamonsinlapatham P; Decroix N; Mihaila-Amrouche L; Bouvet A; Bouvet JP
    Scand J Immunol; 2004 May; 59(5):504-10. PubMed ID: 15140061
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.